(Sharecast News) - Shares in American clinical-stage biopharmaceutical company 89bio rocketed in pre-market trade on Thursday after Swiss pharma giant Roche struck a deal to buy the outfit for up to $3.5bn.
Known for its innovative therapies for the treatment of liver and cardiometabolic diseases, 89bio's pegozafermin product is seen as...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE